Published in

SAGE Publications, Antiviral Therapy, 2(9), p. 297-299, 2004

DOI: 10.1177/135965350400900211

Links

Tools

Export citation

Search in Google Scholar

Safety and efficacy of a NRTI-sparing HAART regimen of efavirenz and lopinavir/ritonavir in HIV-1-infected children.

Journal article published in 2004 by Pieter La A. Fraaij, Jennifer Neubert, Annemarie Mc C. van Rossum, A. M. van Rossum, Alina S. Bergshoeff, Horst Schroten, Ronald de Groot, Nico G. Hartwig, Tim Niehues, Klaus Korn ORCID, David M. Burger, R. de Groot
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Green circle
Published version: archiving allowed
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

We studied a nucleoside reverse transcriptase inhibitor (NRTI)-sparing regimen for the treatment of children infected with NRTI-resistant HIV-1. The combination of lopinavir/ritonavir and efavirenz suppressed HIV-1 levels for a prolonged period and resulted in a significant increase in CD4+ T cell numbers despite an extensive prior treatment with NRTI (>4 years). Observed side effects were transient with the exception of dyslipidaemia.